Alternatives to Moderna

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

Advancing next-generation mRNA medicines.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.

Biopharmaceutical company developing innovative therapies for sepsis and intensive care.

Developing disease-responsive advanced therapies through programmable gene control technology.

A clinical-stage dermatology company developing novel therapies for inflammatory skin diseases.

A University of Cambridge spin-out tackling unmet drug screening needs by combining materials engineering and cell biology.

AI-driven biotechnology company developing novel protein therapeutics through generative biology.

Developing engineered biologics to harness the immune system for disease treatment.

AI-powered platform for developing lipid nanoparticles for oligonucleotide therapies.

Israeli-UK biotech company developing novel RNA therapeutics for rare genetic diseases.

Biopharmaceutical company developing mRNA-based vaccines and therapeutics for infectious diseases and cancer.

A commercial-stage immunotherapy company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases.

Biopharmaceutical startup developing novel therapies for rare genetic diseases.

Clinical-stage biotechnology company developing Antibody Oligonucleotide Conjugates (AOCs) for serious diseases.

Therapeutics company developing novel treatments for complex diseases.

Biotechnology company developing inhaled therapies for genetic diseases, focusing on Cystic Fibrosis.